Haleos Labs
- Market cap
- ₹ 480 Cr.
- P/E
- 27.7x
- P/B
- 2.28x
- 52-week range
- 1,091.1 – 1,774
- ROE
- 8%
- ROCE
- 10%
- Dividend yield
- 0.1%
- Debt / equity
- 0.52
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Haleos Labs Limited, formerly, SMS Lifesciences India Limited, is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Haleos Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)27.7 against a typical 34.6: cheaper than most peers (1st = cheapest).93rd of 220
- Sales growth−11.6% against a typical +15.6% from a year earlier.168th of 197
- Profit growth−58.1% against a typical +18.9% from a year earlier.138th of 160
- Share price, 3 months−7.5% against a typical −0.5%.137th of 200
- Size₹ 480.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).102nd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB by Infomerics- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Infomerics | IVR BBB/ IVR A3+ | Positive | 22 May 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 22 May 2026 | Reaffirmed | IVR BBB/ IVR A3+ | — | Infomerics | ₹ 116.01 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 29 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 11 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 10 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 11 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 29 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 72 | 90 | 93 | 78 | 85 | 89 | 83 | 81 | 95 | 75 | 73 |
| Expenses | 61 | 63 | 79 | 76 | 70 | 72 | 82 | 71 | 68 | 81 | 71 | 64 |
| Operating Profit | 8 | 9 | 11 | 16 | 9 | 13 | 7 | 12 | 14 | 14 | 4 | 9 |
| OPM % | 11.5% | 12.9% | 12.6% | 17.6% | 10.9% | 15.1% | 8.3% | 14.2% | 16.7% | 14.8% | 5.5% | 12.5% |
| Other Income | 0 | 1 | 2 | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 2 | 0 |
| Interest | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 2 | 4 | 7 | 11 | 5 | 7 | 4 | 7 | 8 | 9 | 1 | 3 |
| Tax % | 126.5% | −8.1% | 8.7% | 33.3% | 29.7% | 29.8% | 11.5% | 37.6% | 24.4% | 24.3% | 62.2% | 46.5% |
| Net Profit | −0 | 4 | 6 | 7 | 3 | 5 | 3 | 4 | 6 | 7 | 0 | 2 |
| EPS in Rs | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.9 | 1.46 | 8.77 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 5%
- 3 Years
- 2%
- TTM
- −3%
- 10 Years
- —
- 5 Years
- 5%
- 3 Years
- 20%
- TTM
- −8%
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 42%
- TTM
- —
- 10 Years
- —
- 5 Years
- 8%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Haleos Labs | ₹ 1,445.00 | ₹ 480 Cr. | 27.7x | 2.3x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- N. Rajendra Prasad
- Chief Financial Officer
- Trupti Ranjan Mohanty
- Compliance Officer, Company Secretary
- Veeravenkata Satyanarayana Murthy Tallurl
- Managing Director, Executive Director
- Sudeepthl Goplneedl
- Whole-time Director
- Talluri Venkata Praveen
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.